logo
Alkyl Amines Chemicals surges 8% on healthy outlook; zooms 46% from May low

Alkyl Amines Chemicals surges 8% on healthy outlook; zooms 46% from May low

Alkyl Amines Chemicals share price: Shares of Alkyl Amines Chemicals hit an eight-month high of ₹2,368, surging 8 per cent on the BSE in Wednesday's intra-day trade amid heavy volumes on a healthy business outlook.
The stock of specialty chemicals firm is trading at its highest level since October 2024. It had hit a 52-week high of ₹2,497.95 on September 19, 2024. The stock has bounced back 46 per cent from its previous month low of ₹1,622 touched on May 9, 2025.
Thus far in the calendar year 2025, Alkyl Amines Chemicals has outperformed the market by gaining 28 per cent, as compared to a 5 per cent rise in the BSE Sensex. Track LIVE Stock Market Updates Here
Alkyl Amines outlook
Alkyl Amines Chemicals has established a leading position in the domestic market and a presence in the international market with a reputation for reliable service and quality products. For the financial year 2025-26, the management said the company's focus will continue on sustainable growth by taking measures for increasing its market share of existing products and also introducing new products.
The company's customers in the agrochemicals and pharmaceuticals sectors continue to face global competition from Chinese manufacturers resulting in business uncertainty. This has impacted sales of the company's products to major customers. Dumping of low-price imports of Acetonitrile continues to increase, resulting in a reduction in its sales and creating margin pressures.
Alkyl Amines Chemicals in its FY25 annual report, said that the company has applied for an anti-dumping duty on Acetonitrile imports and is awaiting approval from the Ministry of Finance. The company's sales to the US of total sales is around 4.5 per cent. Change in USA tariffs on some of the company's products may have an impact on volumes and margins for such sales. However, with the global growth of chemicals focused more on Asia, it is expected that there will be further growth in the chemical industry.
In order to meet the growing demand for the company's products, a newly set up plant at an investment cost of ₹400 crore at its existing Kurkumbh site, Maharashtra, for enhancing the manufacturing capacity of Ethyl Amines is fully operational. During the financial year 2025-26, the management expects the company's investments in various other projects to add to both top-line and bottom-line.
Brokerages' view on Alkyl Amines Chemicals
Alkyl Amines Chemicals increased its research and development (R&D) spend to ₹890 crore in FY25 (0.6 per cent of sales), focusing on new product development, process efficiency, and sustainability. It has developed three new products, one set for launch in FY26, with a growing emphasis on value-added innovation and environmental impact reduction.
The company expanded aliphatic amines capacity by ~30 per cent in FY24 and is entering higher margin specialty products. Motilal Oswal Financial Services estimates a revenue/EPS CAGR of 11 per cent/14 per cent over FY25- 27. However, pricing pressure from imports and certain commoditised products poses risks, the brokerage firm said.
Management is hopeful of 10-15 per cent volume growth in FY26 but indicates pricing pressure may be sustained, due to overcapacity in the base amines segment. Alkyl Amines Chemicals has set an ₹150 crore FY26 capex target and expects the new products facility to be completed by December 2025-January 2026.
Regarding anti-dumping duties on acetonitrile, management expects a favourable decision from the Ministry of Finance by late Q2FY26, analysts at Elara Capital said. The brokerage firm expects the company to continue to face margin pressure, due to overcapacity in ethyl amines and its specialty chemicals products. Therefore, analysts decrease EPS of FY26E by 3 per cent and FY27E by 9 per cent.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IDBI Bank Q1FY26 results: Net profit rises 16.75% to ₹2,007 crore
IDBI Bank Q1FY26 results: Net profit rises 16.75% to ₹2,007 crore

Business Standard

time16 minutes ago

  • Business Standard

IDBI Bank Q1FY26 results: Net profit rises 16.75% to ₹2,007 crore

IDBI Bank on Monday reported a 16.75 per cent year-on-year (YoY) increase in standalone net profit to ₹2,007 crore in the April–June quarter (Q1FY26). Net profit in the same quarter last year was ₹1,719 crore, according to a BSE filing by the company. Sequentially, profit dropped by 2.15 per cent from ₹2,051 crore in Q4FY25. Operating profit increased by 13 per cent in Q1FY26 to ₹2,354 crore as against ₹2,076 crore in Q1FY25. Net interest income (NII) stood at ₹3,166 crore in Q1FY26 as against ₹3,233 crore in Q1FY25. Net interest margin (NIM) dropped by 50 basis points to 3.68 per cent in Q1FY26 as compared to 4.18 per cent in Q1FY25. The bank's gross non-performing assets (NPAs) stood at ₹6,384.61 crore, down from ₹7,795.42 crore a year ago. The gross NPA ratio improved to 2.93 per cent from 3.87 per cent, while net NPAs reduced to ₹447 crore from ₹454 crore. The net NPA ratio improved to 0.21 per cent as on June 30, 2025, as against 0.23 per cent as on June 30, 2024. Cost of deposit increased to 4.84 per cent as compared to 4.58 per cent a year ago. Cost of funds also rose to 4.98 per cent in this quarter from 4.81 per cent in Q1FY25. The bank said that its return on equity (RoE) stands at 17.91 per cent, while the cost-to-income ratio stood at 48.86 per cent.

BEML stock split news: Here's what investors need to know
BEML stock split news: Here's what investors need to know

Business Standard

time16 minutes ago

  • Business Standard

BEML stock split news: Here's what investors need to know

BEML share price today: Public sector company, Bharat Earth Movers Ltd. (BEML) disclosed in its recent exchange filing on Monday, July 21, 2025, that the board of directors has greenlit the proposal for a stock split in the ratio of 1:2. On Monday, BEML shares closed the trading session at ₹4,372, down by 0.67 per cent on the National Stock Exchange. "The record date for the purpose of above sub-division/ split of Equity Shares shall be decided after obtaining approval for sub-division/ split from the shareholders and will be intimated in due course," the exchange filing read. What this means for investors? BEML's board approval for a 1:2 stock split means that each existing equity share of face value ₹10 (fully paid up) will be sub-divided into two equity shares of face value ₹5 each (fully paid up). A stock split increases the number of outstanding shares in the market without adjusting the value of an investor's total holdings. While this reduces the price of each equity share, the overall market capitalisation of the company stays the same. The company mentioned in its exchange filing that the move is aimed at complying with the capital restructuring guidelines of the Department of Investment and Public Asset Management (DIPAM). This stock split will also make the stock more accessible for small investors and improve the overall liquidity of the company shares in the market. BEML share price So far this calendar year, BEML shares have witnessed a single-digit rise of 8 per cent on the BSE. However, in the last 3-month period, the shares of the defence company have experienced a surge of 38 per cent. The defence stock is trading above its 52-week low of ₹2,350, touched earlier this year. The current market capitalisation of the company stands at ₹18,206.98 crore. BEML financials BEML reported a double digit surge of 12 per cent in its profit after tax (PAT) to ₹287.5 crore in the fourth quarter of the financial year 2024-2025 (Q4FY25), from ₹256.80 crore reported in the corresponding quarter of the previous fiscal year. Revenue from operations stood at ₹1,652.53 crore in Q4FY25, up by 9.18 per cent from ₹1,513.65 crore reported in Q4FY24. As per Elara Capital, the robust performance trajectory might take a breather in the coming quarter due to sluggish execution of orders. "BEML revenue may rise 6 per cent due to the slowdown in railway orders execution," the brokerage firm stated in its report.

Stock market update: Nifty Pharma index falls 0.27%
Stock market update: Nifty Pharma index falls 0.27%

Economic Times

time16 minutes ago

  • Economic Times

Stock market update: Nifty Pharma index falls 0.27%

NEW DELHI: The Nifty Pharma index closed on a negative note on Monday. ADVERTISEMENT Shares of J B Chemicals & Pharmaceuticals Ltd.(up 1.86 per cent), Gland Pharma Ltd.(up 0.67 per cent), Laurus Labs Ltd.(up 0.3 per cent), Ajanta Pharma Ltd.(up 0.16 per cent) and Dr. Reddy's Laboratories Ltd.(up 0.15 per cent) ended the day as top gainers in the pack. On the other hand, Natco Pharma Ltd.(down 1.89 per cent), Glenmark Pharmaceuticals Ltd.(down 1.83 per cent), Biocon Ltd.(down 1.03 per cent), Divi's Laboratories Ltd.(down 0.65 per cent) and Lupin Ltd.(down 0.58 per cent) finished as the top losers of the day. The Nifty Pharma index closed 0.27 per cent down at 22531.85. Benchmark NSE Nifty50 index ended up 122.3 points at 25090.7, while the BSE Sensex stood up 442.61 points at 82200.34. Among the 50 stocks in the Nifty index, 31 ended in the green, while 19 closed in the red. ADVERTISEMENT Shares of Vodafone Idea, YES Bank, JP Power, PC Jeweller and Paradeep Phosphates were among the most traded shares on the NSE. Shares of Gallantt Metal, Paradeep Phosphates, Borosil Renewables, Mangalore Chem and Bluspring Enterprises Ltd. hit their fresh 52-week highs in today's trade, while Shriram EPC(PP), Smartworks Coworking, Reliance Comm, SKIL Infrastructure and LCC Infotech hit their fresh 52-week lows. ADVERTISEMENT (You can now subscribe to our ETMarkets WhatsApp channel)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store